Duramycin: Exploring the therapeutic frontier of a unique lantibiotic

This review evaluates duramycin, a lantibiotic antimicrobial peptide, focusing on its biochemical properties, biosynthetic mechanisms, structural characteristics, and therapeutic applications. We examine the critical role of lanthionine and methyllanthionine in antimicrobial efficacy and trace duramycin's development trajectory. Molecular analysis of duramycin highlights the significance of post-translational modifications and leader peptide interactions in its functionality. The peptide's mechanism of action, which involves disrupting membrane integrity through phosphatidylethanolamine binding, forms the foundation of its antimicrobial activity. We assess duramycin's clinical progress, particularly its advancement to Phase II trials for cystic fibrosis therapy, and evaluate its potential against viral infections. The review addresses challenges in production, resistance development, and clinical delivery while exploring emerging applications in cancer treatment, diagnostics, and molecular probes for studying membrane dynamics. We conclude by examining future directions for lantibiotic engineering and the broader implications of duramycin research for antimicrobial therapy and biomedicine.